Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
American Brivision (Holding) C - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABVC
Over the counter
8731
http://www.ecologycoatings.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for American Brivision (Holding) C
ABVC: Developing a Growing Portfolio Of Plant-Based Therapies With Strong Prospects
- Jan 27th, 2021 9:55 am
American BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021
- Jan 6th, 2021 2:00 pm
American BriVision Issues Clinical Study Report for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
- Nov 9th, 2020 2:00 pm
American BriVision Issues Clinical Study Report for Vitargus First-in-Human Phase I Clinical Trial
- Sep 9th, 2020 1:00 pm
American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder
- Aug 24th, 2020 1:00 pm
American BriVision Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD
- Jul 28th, 2020 1:00 pm
American BriVision Announces Completed Patient Enrollment in Clinical Trial at UCSF for Treatment of Adult ADHD
- Jun 15th, 2020 1:00 pm
American BriVision Increases Size of Private Placement to Raise $2 Million
- May 21st, 2020 1:00 pm
American BriVision Announces Two Financial Transactions to Improve Working Capital and Reduce Debt
- Apr 13th, 2020 1:00 pm
American BriVision Conducts Site Monitoring Visit for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
- Apr 6th, 2020 1:00 pm
American BriVision First Patient Enrolled for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
- Mar 4th, 2020 2:00 pm
Scroll